Nirsevimab has been recently licensed for universal RSV prophylaxis in infants. NIRSE-GAL is a three-year population-based study initiated in Galicia in September 2023.

Building on the 2023 session held at the ESWI conference in Valencia "RSV Looking towards the future", this one-day summit concentrated on the healthcare and economic impact of RSV disease, along with the potential solutions expected in the near future.

With promising developments in the field of respiratory viral infections, the conference sessions covered hot topics on seasonal, pandemic, and zoonotic influenza viruses, as well as other respiratory viruses such as RSV and SARS-CoV-2.

In this episode, ECDC expert on respiratory viruses, Nick Bundle, gives the lowdown on the European Respiratory Virus Surveillance Summary (ERVISS), a new surveillance tool which presents weekly data on influenza, SARS-CoV-2 and RSV.

The discussions highlighted the crucial role of prevention, treatment and access to immunisation programmes to raise awareness and decrease the cases of RSV hospitalisations and deaths of young children and older adults.

Respiratory syncytial virus (RSV) is the leading cause of hospitalisation for respiratory infection in young children.

Conclusions by Peter Openshaw, Co-Chair of the the ESWI Respiratory Virus Summit 2024

By Ab Osterhaus, Host of the ESWI Respiratory Virus Summit 2024

Live attenuated vaccines; NIRSE-GAL: Evaluation of the effectiveness and impact of Nirsevimab in Galicia; and Therapeutics

ESWI Summit 2024: Early Career Scientists They each delivered a presentation introducing themselves and their ongoing work on RSV, bringing innovative ideas and making clear calls for action.

Keynote Lecture by Dexter Wiseman, Imperial College London

Keynote Lecture by Stefan Gravenstein, Brown University